KEAP1 and cancer: While KEAP1 inhibition would be one approach to induce NRF2, it is dangerous: mutations in KEAP1 or in the KEAP1-binding motif of NRF2 cause cancer.92TRIP12 variants have been observed in cancer but are unlikely to be driver mutations.